- Home
- AYTU vs LPCN Comparison
AYTU vs LPCN Comparison
Compare AYTU & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- LPCN
- Stock Information
- Founded
- AYTU N/A
- LPCN 1997
- Country
- AYTU United States
- LPCN United States
- Employees
- AYTU N/A
- LPCN N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- LPCN Health Care
- Exchange
- AYTU Nasdaq
- LPCN Nasdaq
- Market Cap
- AYTU 19.7M
- LPCN 16.1M
- IPO Year
- AYTU N/A
- LPCN N/A
- Fundamental
- Price
- AYTU $2.37
- LPCN $2.85
- Analyst Decision
- AYTU Strong Buy
- LPCN Strong Buy
- Analyst Count
- AYTU 2
- LPCN 2
- Target Price
- AYTU $10.00
- LPCN $9.00
- AVG Volume (30 Days)
- AYTU 100.5K
- LPCN 15.1K
- Earning Date
- AYTU 11-12-2025
- LPCN 11-06-2025
- Dividend Yield
- AYTU N/A
- LPCN N/A
- EPS Growth
- AYTU N/A
- LPCN N/A
- EPS
- AYTU N/A
- LPCN N/A
- Revenue
- AYTU $81,659,000.00
- LPCN $4,208,119.00
- Revenue This Year
- AYTU N/A
- LPCN N/A
- Revenue Next Year
- AYTU $2.00
- LPCN N/A
- P/E Ratio
- AYTU N/A
- LPCN N/A
- Revenue Growth
- AYTU 0.41
- LPCN N/A
- 52 Week Low
- AYTU $0.95
- LPCN $2.68
- 52 Week High
- AYTU $2.85
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- AYTU 55.75
- LPCN 39.71
- Support Level
- AYTU $2.21
- LPCN $2.87
- Resistance Level
- AYTU $2.58
- LPCN $3.08
- Average True Range (ATR)
- AYTU 0.13
- LPCN 0.10
- MACD
- AYTU 0.01
- LPCN 0.00
- Stochastic Oscillator
- AYTU 48.78
- LPCN 0.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.